Discover opportunities months before the RFP drops
Learn more →Retrieving contract details... Hang tight!
See what competitors charge and their contract structure
Spot renewal opportunities 6-12 months before expiration
Analyze buyer's purchasing history and vendor preferences
Track expiration dates across all your target accounts
Reach decision-makers before renewal with competitive intel
Our customers win 3x more contract renewals and replacements
Premium
Clean & enrich your CRM automatically
Premium
Get complete source documentation & analysis
This contract includes 1 purchase order from Sep 1, 2022 to Sep 1, 2022
| Buyer | Vendor | Issued Date | Quantity |
|---|---|---|---|
| Office of Acquisition Managementt Policy | ARCTURUS THERAPEUTICS, INC. | Sep 1, 2022 | 1 |
Full Purchase Intelligence Available
Get complete pricing, descriptions, and financial details for all 1 purchase orders
Unlock Full Details →See what competitors charge and their contract structure
Spot renewal opportunities 6-12 months before expiration
Analyze buyer's purchasing history and vendor preferences
Track expiration dates across all your target accounts
Reach decision-makers before renewal with competitive intel
Our customers win 3x more contract renewals and replacements
No public files available for this contract.
Contract documentation may be available through official government sources or agency portals. Starbridge can help you track down and retrieve these files.
THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO ASSESS THE ABILITY OF AURAVAX THERAPEUTICS? (AURAVAX) NOVEL MUCOSAL ADJUVANT NANOSTING-002, TOGETHER WITH INFLUENZA LIVE ATTENUATED VIRUS (LAV) CREATED WITH CODAGENIX NOVEL SYNTHETIC ATTENUATED VIRUS ENGIN
Effective Date
Sep 23, 2024
Expires
Effective: Sep 23, 2024
THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO ASSESS THE ABILITY OF AURAVAX THERAPEUTICS? (AURAVAX) NOVEL MUCOSAL ADJUVANT NANOSTING-002, TOGETHER WITH INFLUENZA LIVE ATTENUATED VIRUS (LAV) CREATED WITH CODAGENIX NOVEL SYNTHETIC ATTENUATED VIRUS ENGIN
ActiveDEVELOPMENT OF CD388 AS A LONG-LASTING PROPHYLACTIC ANTI-VIRAL OPTION FOR PROTECTION AGAINST THE HEALTH IMPACTS CAUSED BY INFLUENZA
Effective Date
Sep 30, 2025
Expires
Effective: Sep 30, 2025
DEVELOPMENT OF CD388 AS A LONG-LASTING PROPHYLACTIC ANTI-VIRAL OPTION FOR PROTECTION AGAINST THE HEALTH IMPACTS CAUSED BY INFLUENZA
ActiveADVANCE THE DEVELOPMENT OF POTENT, CROSS-REACTIVE MULTISPECIFIC ANTIBODIES FOR THE PREP COUNTERMEASURE OF COVID-19 AND SEASONAL AND HIGHLY PATHOGENIC AVIAN INFLUENZA.
Effective Date
Sep 27, 2023
Expires
Effective: Sep 27, 2023
ADVANCE THE DEVELOPMENT OF POTENT, CROSS-REACTIVE MULTISPECIFIC ANTIBODIES FOR THE PREP COUNTERMEASURE OF COVID-19 AND SEASONAL AND HIGHLY PATHOGENIC AVIAN INFLUENZA.
ActiveTHE OVERALL OBJECTIVE OF THIS CONTRACT IS TO DEMONSTRATE THE VERSATILITY AND EFFICACY OF OUR PROGRAMMABLE ANTIVIRAL TECHNOLOGY PLATFORM BY ASSEMBLING THE PRECLINICAL PACKAGE FOR LNA14, PERFORMING A PHASE 1A STUDY IN HEALTHY ADULT HUMAN SUBJECTS, AND
Effective Date
Sep 30, 2024
Expires
Effective: Sep 30, 2024
THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO DEMONSTRATE THE VERSATILITY AND EFFICACY OF OUR PROGRAMMABLE ANTIVIRAL TECHNOLOGY PLATFORM BY ASSEMBLING THE PRECLINICAL PACKAGE FOR LNA14, PERFORMING A PHASE 1A STUDY IN HEALTHY ADULT HUMAN SUBJECTS, AND
ActiveSee who's winning contracts, track spending trends, and identify your best opportunities before your competition.
Schedule Your Demo →Premium
Clean & enrich your CRM automatically
Premium
Get complete source documentation & analysis